The production of interleukin-6 (IL-6) has been discovered in a variety of human tumors. Here we report the expression of IL-6, IL-6 receptor a (IL-6Ra), and gp130 in human esophageal carcinoma tissues. We further demonstrate that IL-6 protects an esophageal carcinoma cell line CE48T/VGH from apoptosis induced by staurosporine. IL-6 stimulation induced a rapid phosphorylation of gp130 and STAT3, and a dominant-negative STAT3 completely abolished the antiapoptotic effect. IL-6 also activated ERK 1/2 in CE48T/VGH cells. Inhibition of the ERK activation by PD98059 and transfection of a dominant-negative ERK2 completely blocked the protection of IL-6 against apoptosis. Thus, both STAT and MAP kinase pathways are responsible for the IL-6-delivered survival signal in human esophageal carcinoma cells. In contrast, PI3-K inhibitors only partially attenuated the effect of IL-6, suggesting that PI3-K does not play a major role in the antiapoptotic signal of IL-6 in our system. To investigate whether IL-6 could induce the production of antiapoptotic molecules, proteins of the Bcl-2 family were measured. While Bcl-2, Bcl-x L, , and Bax were not affected, Mcl-1 was induced by IL-6 in human esophageal carcinoma cells. Our results suggest that IL-6 may contribute to the progression of esophageal cancers in an autocrine or paracrine manner.
Introduction
The infiltration of lymphocytes and monocytes is frequently observed in tumor tissues from a variety of origins, such as carcinomas of the rectum, pharynx, breast, liver, and lung (Halapi, 1998) . In esophageal carcinomas, infiltrating lymphocytes and monocytes in the tumor mass are detected in over 50% of the patients (Ma et al., 1999) . These cells and the cytokines that they secrete may modulate the local immune response in the surroundings and affect the growth of tumor cells (Mocellin et al., 2001) .
The incidence of esophageal carcinoma exhibits geographical variations, with high frequency in certain regions of Africa and Asia (Blot, 1994) . It is the sixth leading cause of cancer death in males in Taiwan. It represents one of the most malignant tumors for its aggressive behavior and poor prognosis. Epidemiological investigations have revealed some risk factors associated with esophageal cancers, such as alcohol and cigarette abuse, diet, nutritional deficiencies, or exposure to infectious agents (Ribeiro et al., 1996) . In addition, chronic irritation of the esophageal epithelium, for example, thermal or mechanical injuries, can also contribute to the development of esophageal tumors. These risk factors may recruit monocytes, lymphocytes, and fibroblasts to advance wound healing and repair process. Interleukin-6 (IL-6) has been found in higher levels in wound fluids (Mateo et al., 1994; Gallo et al., 1997) and in tumors (Kawano et al., 1988; Meir et al., 1990; Okamoto et al., 1997) . In multiple myelomas, IL-6 is known to be an autocrine growth factor and to protect them from apoptosis induced by various stimuli (Lauta, 2001) . Evidence has been accumulating that IL-6 is an autocrine and paracrine growth factor for prostate cancer cell lines (Smith et al., 2001) and may contribute to the progression of prostate cancer (Chen et al., 2001) . The expression of IL-6 and IL-6R mRNA has been detected in human esophageal carcinoma cells (Oka et al., 1995) . The level of IL-6 was elevated in sera and in tumor tissues in patients with carcinoma of the esophagus (Oka et al., 1996) . These findings suggest that IL-6 may exert biological functions on esophageal carcinoma cells.
IL-6 receptor (IL-6R) is composed of a ligand binding a subunit and a signal-transducing component, gp130. The binding of IL-6 to IL-6Ra triggers the homodimerization of gp130 and activates Janus kinases (JAK). Subsequently, gp130 is phosphorylated by JAK and the phosphotyrosines recruit signal transducers and activators of transcription 3 (STAT3) and a protein tyrosine phosphatase SHP-2 (Taga, 1997) . After tyrosine phosphorylation, STAT3 forms a homodimer or a heterodimer with STAT1 and enters the nucleus, where it regulates the expression of a specific set of genes (Hirano et al., 2000) . In hematopoietic cells, the phosphorylation of SHP-2 leads to the association of SHP-2 with GRB2, which in turns activates the MAP kinase pathway . It has been reported that phosphorylation of Ser-727 of STAT3 is also required for the maximal transcriptional activity (Wen et al., 1995) , and may be mediated by the MAP kinase family (Zhang et al., 2001) . In addition to JAK/STAT and MAP kinase pathways, IL-6 was also shown to activate phosphatidyl inositol 3-kinase (PI3-K) in prostate cancers (Qiu et al., 1998) and hepatocellular carcinoma cells (Chen et al., 1998) . Among all the signaling pathways that IL-6 activates, STAT3 has been shown to be a central player in mediating cell growth, differentiation, and survival signals. However, the functions of other IL-6-activated pathways are beginning to be elucidated (Hirano et al., 2000) . In pro-B cells, IL-6-activated MAPK was essential for mitogenesis, but not for antiapoptosis . Selective inhibition of the p44/p42 MAP kinase pathway blocked proliferation in response to IL-6 in cholangiocarcinoma cell line (Park et al., 1999) . In contrast, the PI3 kinase pathway activated by IL-6R signals was responsible for the differentiation of prostate carcinoma cells (Qiu et al., 1998) and for the survival of hepatocellular carcinoma cells (Chen et al., 1998) . The biological effects, which are mediated through various signaling pathways transduced by IL-6R in esophageal carcinoma cells, remain to be investigated.
A unique finding in this study is that both STAT3 and MAP kinase signaling pathways are required for the antiapoptotic effect of IL-6 in human esophageal carcinoma cells, whereas PI3-K does not play an important role in IL-6-mediated protection.
Results

IL-6 and IL-6 receptor are expressed in human esophageal carcinoma tissues
The expression of IL-6 and IL-6 receptor genes was measured in cDNA of 18 human esophageal carcinoma specimens by RT-PCR. Both the tumorous (T) and adjacent appeared-normal (N) portions of all samples expressed the mRNA of IL-6 (Figure 1a ). Among them, 11 out of 18 (no. 2, 3, 5, 7, 8, 10, 11, 12, 15, 16, and 17) tumor tissues expressed a higher amount of IL-6 than the corresponding adjacent tissues, whereas the level of IL-6 was similar in tumorous and adjacent tissues in other samples. All the specimens also expressed IL-6Ra and gp130 chains. However, no significant difference in the expression of IL-6Ra and gp130 between tumorous and adjacent portions was seen in all tissue specimens (data not shown). The immunohistochemical staining of IL-6 (Figure 1b ) was seen intensely in the cytoplasm of the esophageal carcinoma cells, while no staining was detected using normal mouse IgG (Figure 1c ). The result indicates that esophageal carcinoma cells produce IL-6. Thus, the IL-6 autocrine or/and paracrine system may exist in esophageal carcinomas.
IL-6 alone does not stimulate the growth of CE48T/VGH cell line
To investigate the function of IL-6 in esophageal carcinomas, a human esophageal carcinoma cell line CE48T/VGH was chosen for the following study. Figure 2 shows that CE48T/VGH cells express IL-6Ra IL-6 prevents apoptosis in human esophageal carcinoma C-M Leu et al and gp130 as detected by immunoprecipitation followed by Western blotting. However, CE48T/VGH cells do not secrete IL-6 as measured by enzyme-linked immunosorbent assay (ELISA) (data not shown). Thus, CE48T/VGH is suitable for the study of IL-6-delivered signaling pathways. To study the effect of IL-6 on the growth of CE48T/VGH, various concentrations of IL-6 were added. We found that IL-6 did not promote the proliferation of CE48T/VGH cells under serum-free (SF) conditions (data not shown), suggesting that IL-6 alone could not stimulate the growth of CE48T/VGH cells.
IL-6 prevents apoptosis in CE48T/VGH cells
To test whether IL-6 could serve as a survival factor for CE48T/VGH, staurosporine (ST), a wide-spectrum protein kinase inhibitor, was used to induce apoptosis (Leu et al., 2000) and the protective effect of IL-6 was examined. While 2.6% of CE48T/VGH underwent apoptosis under SF conditions, only 0.6% of the cells showed micronucleated morphology in the presence of IL-6 (Figure 3a) . Treatment of ST resulted in an increase of apoptotic cells to 36.7%. When IL-6 was added to the culture medium, apoptosis was reduced to 13.2% (Po0.012, Student's t-test) (Figure 3a) . The antiapoptotic function of IL-6 was further confirmed by two other apoptosis assays. Using TUNEL assay followed by flow cytometry, we found that IL-6 suppressed STinduced apoptosis in a dose-dependent manner (Figure 3b ). At the concentrations of 10 ng/ml, IL-6 reached the maximal protective effect; apoptosis was reduced from 43.1 to 21.6%. Higher concentrations of IL-6 could not further reverse the ST-induced apoptosis. IL-6 also reduced the cleavage of poly(ADP-ribose) polymerase (PARP) into an 85-kDa fragment, another characteristic of apoptotic cells, as early as 12 h following treatment, and this effect lasted for at least 30 h (Figure 3c ). The antiapoptotic effect of IL-6 was IL-6 prevents apoptosis in human esophageal carcinoma C-M Leu et al also demonstrated on CE48T/VGH cells treated with cisplatin (Enzinger et al., 1999) , a chemotherapeutic drug often used for the treatment of esophageal cancer (data not shown).
STAT3 is essential for the antiapoptotic signal of IL-6
To investigate how IL-6 exerts its antiapoptotic function in CE48T/VGH cells, phosphorylation of gp130 and STAT3 was measured. We found that IL-6 triggered tyrosine phosphorylation of gp130 as detected by immunoprecipitation with an anti-gp130 antibody (Ab) followed by Western blotting using an antiphosphotyrosine Ab (Figure 4a ). Furthermore, IL-6-induced tyrosine phosphorylation of STAT3 occurred within 2 min and lasted for at least 30 min after the exposure to IL-6 ( Figure 4b ). To prove that STAT3 is essential for the antiapoptotic function of IL-6, we transiently cotransfected a STAT3 dominant-negative mutant STAT3F (Nakajima et al., 1996) MAP kinase pathway is also essential for the antiapoptotic signal of IL-6
To investigate the role of the MAP kinase pathway in the apoptotic effect of IL-6, we first measured whether IL-6 induced ERK kinase activity in an in vitro kinase assay. After various treatments of CE48T/VGH cells, ERK1 and ERK2 were immunoprecipitated with an anti-ERK Ab. An ERK substrate Elk-1 was then mixed with the immunoprecipitates to carry out kinase reaction in vitro. Phosphorylated Elk-1 was detected by Western blotting with an antiphosphoserine Elk-1 Ab. As shown in Figure 5a , a basal ERK activity was detected in CE48T/VGH cells cultured under SF conditions or treated with ST. The addition of IL-6 stimulated the phosphorylation of Elk-1 regardless of the presence of ST. When a MEK inhibitor PD98059 was added, the activation of ERK by IL-6 was fully reversed (Figure 5a ). These results demonstrated that IL-6 triggered the activation of the MEK/ERK pathway. We next examined whether the antiapoptotic function of IL-6 is mediated through the MEK/ERK pathway. Both Hoechst 33258 staining ( Figure 5b ) and TUNEL assay (Figure 5c ) demonstrated that PD98059 completely inhibited the antiapoptotic effect of IL-6. To further prove that the MAP kinase pathway plays an essential role in the antiapoptotic signaling of IL-6, an ERK2 dominant-negative mutant ERK2 (YF) (Robbins et al., 1993) was transiently transfected into CE48T/VGH Figure 4 Requirement of STAT3 in the antiapoptotic function of IL-6. (a, b) gp130 and STAT3 were tyrosine-phosphorylated by the addition of IL-6 to CE48T/VGH cells. Cells were seeded in 5% FCS-containing DMEM overnight and then maintained in SF medium for 24 h. Fresh SF medium containing 100 ng/ml IL-6 was added to cells. The cell lysate was prepared at the indicated times and immunoprecipitated by anti-gp130 (a) or anti-STAT3 (b) Ab; phosphorylated gp!30 or STAT3 was detected by Western blotting using an antiphosphotyrosine (PY) Ab, 4G10. The same membranes were stripped and reacted with anti-gp130 or anti-STAT3 to reveal the amount of the immunoprecipitated proteins. (c) STAT3 was essential for the anti apoptotic function of IL-6. Cells were transiently cotransfected with pCMV-b and STAT3 (wt) or STAT3 dominant-negative mutant STAT3F. After 2 days, cells were maintained in DMEM containing 0.2% FCS for 24 h, treated with 25 nM ST in the presence or absence of 100 ng/ml IL-6 for another 48 h, and stained with anti-b-galactosidase mAb followed by Texas red-conjugated goat anti-mouse Ig to identify the transfected cells. The nuclei were stained with Hoechst 33258 to reveal the nuclear morphology. The percentage of apoptotic cells in total transfected cells was counted under fluorescence microscopy IL-6 prevents apoptosis in human esophageal carcinoma C-M Leu et al cells. As shown in Figure 5d , the antiapoptotic effect of IL-6 was completely abolished in ERK2 (YF)-transfected cells. Taken together, these data clearly show that the MAP kinase pathway is also essential in the antiapoptotic function of IL-6.
PI3-K does not play a major role in the antiapoptotic signal of IL-6
To investigate the role of the PI3 kinase pathway in our system, PI3-K inhibitor, wortmannin or Ly294002, was added to the cells. As shown in Figure 6a , while 39.2% of CE48T/VGH cells underwent apoptosis after treatment with ST, 21.7% did in the presence of IL-6 (ST þ IL-6). In the presence of wortmannin, IL-6 still retained some antiapoptotic effect (ST þ IL-6 þ W1: 28.9%; ST þ IL-6 þ W2: 33.6%; ST þ IL-6 þ W5: 32.3%). The differences between ST þ IL-6 and ST þ IL-6 þ W were not statistically significant. Thus, the PI3 kinase pathway does not seem to be a major pathway in the antiapoptotic effect of IL-6 (Figure 6a) . Similarly, Ly294002 only partially inhibited the protective effect of IL-6 on the apoptosis induced by ST (Figure 6b ; ST: 46.6%; ST þ IL-6: 29.5%; ST þ IL-6 þ Ly2: 36.6%; ST þ IL-6 þ Ly5: 37.7%). The differences between ST þ IL-6 and ST þ IL-6 þ Ly were not statistically significant. Higher concentrations of Ly294002 were not used due to the cytotoxicity in CE48T/VGH cells (data not shown). These results indicate that inhibition of PI3-K only attenuated the IL-6-induced protection. Thus, PI3-K does not play a major role in the antiapoptotic activity of IL-6 in our system.
IL-6 induces the expression of Mcl-1
In view of the possibility that IL-6 may prevent apoptosis by inducing expression of antiapoptotic genes, we next tested if IL-6 could regulate the expression of proapoptotic or antiapoptotic molecules. The members of Bcl-2 family proteins were measured by Western blotting. As shown in Figure 7a , the levels of Bcl-2, Bclx L , or Bax proteins in CE48T/VGH cells were not affected in the presence of ST, and the addition of IL-6 did not alter the amounts of these proteins. In contrast, Mcl-1 was induced by IL-6 in a dose-dependent manner regardless of the absence or the presence of ST (Figure 7b ). At 100 ng/ml, IL-6 induced a 3.1-fold 
Discussion
IL-6 is a multifunctional cytokine with pleiotropic activities on a variety of cell types. It is usually produced at local tissue sites during infection, trauma, or other stress. Apart from its role in inflammation, IL-6 induces differentiation and development of B cells, T cells, myeloid cells, megakaryocytes, osteoclasts, neural cells, and hepatocytes (reviewed in Hirano, 1998) . IL-6 can also act as a growth or survival factor for carcinoma cells; however, the signaling pathways involved are less understood in carcinoma cells than in hematopoietic cells. In this study, we demonstrate that all the esophageal carcinoma tissues express mRNA of IL-6, IL-6Ra, and gp130. The expression of IL-6 mRNA is higher in the carcinoma than in the adjacent tissues in some, but not all samples. The IL-6 protein is also clearly shown in some esophageal carcinoma tissues. Thus, autocrine and/or paracrine sources of IL-6 may play an important role in esophageal carcinogenesis. A human esophageal carcinoma cell line CE48T/VGH, which expresses IL-6Ra and gp130 but does not secrete IL-6, was then chosen for the study of IL-6-delivered signaling pathways. We found that IL-6 alone did not stimulate the proliferation of CE48T/VGH cells. However, IL-6 protected the cells from apoptosis as measured by micronucleation, TUNEL assay, and PARP degradation. The protective effect of IL-6 can be demonstrated on apoptotic cells treated with ST, a protein kinase inhibitor, or with cisplatin, a chemotherapeutic drug often used for the treatment of esophageal cancers (Enzinger et al., 1999) . These results suggest that the antiapoptotic effect of IL-6, secreted either by esophageal carcinoma cells or by stroma cells and infiltrating mononuclear cells, provides an advantageous factor for the survival of esophageal cancers. Similar to the findings in pro-B cell line, T cell, and multiple myeloma Takeda et al., 1998; Catlett-Falcone et al., 1999) , STAT3 plays an essential role in antiapoptotic signals of IL-6 on CE48T/ VGH cells since the transfection of STAT3 dominantnegative mutant STAT3 completely inhibited the function of IL-6. These findings underlie the importance of STAT3 in the antiapoptotic function of IL-6 in various cell types. Activation of STAT3 in B cells and in human myeloma cells induces the expression of antiapoptotic genes such as bcl-2 (Fukada et al., 1996) and bcl-x L Figure 6 Wortmannin and Ly294002 attenuate the antiapoptotic function of IL-6. Cells were prepared and treated as described in Figure 5b except that various concentrations of wortmannin (a, Wl: 1 mM; W2: 2 mM; W5: 5 mM) or Ly294002 (b, Ly2: 2 mM; Ly5: 5 mM) were added to the cells 4 h before the addition of IL-6 Figure 7 Effect of IL-6 on the level of Bcl-2 family proteins. Cells were seeded in 5-cm plates and treated as described in Figure 3 . Cell lysates were prepared after 4 or 8 h and 50 mg protein was used to perform Western blotting. (a) IL-6 did not affect the amount of Bcl-2, Bcl-x L, and Bax in the presence of ST (ST/6). EGF, which was able to rescue ST-induced apoptosis (ST/E), also did not affect these proteins (27). (b) IL-6 upregulated Mcl-1 in the absence or presence of ST. The Western blotting was performed 8 h after treatment IL-6 prevents apoptosis in human esophageal carcinoma C-M Leu et al (Bromberg et al., 1999; Catlett-Falcone et al., 1999) , protecting from Fas-dependent apoptosis. In contrast, IL-6 does not induce Bcl-2 or Bcl-x L , but induces another antiapoptotic protein Mcl-1 in CE48T/VGH cells. The discrepancy between different cell types may be attributed to the difference in cellular content. It has been reported that the activated STAT3 could bind to an SIE-like binding site in the mouse mcl-1 promoter and increase Mcl-1 expression in v-src-transformed NIH3T3 cells (Epling-Burnette et al., 2001) . In addition, a JAK2 inhibitor was able to suppress both STAT3 activation and Mcl-1 upregulation by IL-6 in human myeloma cells (Puthier et al., 1999) . However, IL-6-induced Mcl-1 expression was not mediated by STAT3 pathway in a hepatocellular carcinoma cell line Hep3B (Kuo et al., 2001) . Whether STAT3 transactivates the expression of Mcl-1 in CE48T/VGH cells needs further investigation.
The MAP kinase pathway is also required for the survival function of IL-6 in esophageal carcinoma cells. Our data provide two lines of evidence to identify the importance of the MAP kinase pathway in antiapoptotic activity of IL-6. A MEK-specific inhibitor PD98059 abrogated both the IL-6-induced activation of ERK and the antiapoptotic function of IL-6. Furthermore, transient expression of dominant-negative ERK2 mutant, ERK2 (YF), substantially inhibited the survival effect of IL-6. These results highlight the critical role of the MAP kinase pathway in IL-6 antiapoptotic signal. The requirement of MAPK in antiapoptotic effect in our finding is particularly interesting since the MAP kinase pathway has been reported to be dispensable for other growth factors or cytokines to prevent apoptosis. For instance, the activation of MAPK was essential for mitogenic, but not for antiapoptotic signal of gp130 in pro-B cells (Qiu et al., 1998) . In fibroblasts, the antiapoptotic function of insulin-like growth factor I (IGF-I) was independent of the MAPK activity (Kulik and Weber, 1998; Kulik et al., 1997) . The ability of IGF-I to prevent hyperosmotic stress-induced apoptosis in neuroblastoma cells was not influenced by the MEK inhibitor PD98059 (Singleton et al., 1996) . One plausible explanation is that different cellular contents determine the major signals to prevent cell death; thus some of the other minor ones are dispensable. The PI3 kinase pathway has been shown to be necessary for the survival signals in many cell types (Yao and Cooper, 1995; Minshall et al., 1996; Kulik and Weber, 1998; Kulik et al., 1997; Chen et al., 1998) . However, inhibition of PI3-K only attenuated the protective effect of IL-6 in our system. Thus, PI3-K does not seem to play an important role in IL-6-induced antiapoptosis in esophageal carcinoma cells.
An interesting finding in this study is that both STAT3 and MAP kinase signal pathways are required for the antiapoptotic effect of IL-6 in CE48T/VGH. Blockade of either one of the pathways completely reverted the protective effect of IL-6. An interaction between MAP kinase and STAT3 signaling may explain the cooperative activity in human esophageal carcinoma cells. In addition to tyrosine phosphorylation, serine phosphorylation of STAT3 on Ser-727 induced by different MAP kinase family members, including ERKs, JNKs, and p38, was shown to modulate STAT3 transactivation activities (Wen et al, 1995; Lim and Cao, 1999; Schuringa et al., 2000; Abe et al., 2001; Zhang et al., 2001) . For example, EGF-induced Ser-727 phosphorylation of STAT3 was mediated by ERK but not JNK or p38 MAPKs (Chung et al., 1997) . In addition, UVA-induced Ser-727 phosphorylation of STAT3 may be mediated through ERK, JNK, and p38 MAPKs (Zhang et al., 2001) . The phosphorylation on both Tyr-705 and Ser-727 is required for the maximal transcriptional activity of STAT3 by growth factor or cytokine stimulations (Wen et al., 1995; Abe et al., 2001) . It is unclear if Ser-727 phosphorylation of STAT3 is induced by IL-6 and also required for IL-6-mediated antiapoptotic effect in CE48T/VGH cells. Whether any one of the MAP kinase family members, especially ERKs, is involved in IL-6-induced STAT3 activation in this study is not known. If MEK/ERK induced by IL-6 is necessary for the maximal activation of STAT3, this would explain the observation that MEK inhibitor completely blocked the antiapoptotic effect of IL-6. On the other hand, the role of STAT3 in the antiapoptotic signal of the MEK/ERK pathway is still obscure. Cotransfection of v-raf and dominant-negative STAT3 mutant will uncover more details about the interactions between these two pathways.
Taken together, it seems that the antiapoptotic function of IL-6 needs more than one signaling pathway. How IL-6-activated multiple pathways cross talk may depend on cell types and apoptosis-inducing agents. The mechanisms underlying this complex network of cellular information processing are far from being understood.
Materials and methods
Materials
Human IL-6 was purchased from R&D Systems (Minneapolis, MN, USA). ST, cycloheximide, wortmannin, and Hoechst 33258 were from Sigma (St Louis, MO, USA). PD98059 and Ly294002 were from Calbiochem (La Jolla, CA, USA). Elk-1 fusion protein was from New England Biolabs (Beverly, MA, USA). Rabbit anti-PARP, rabbit anti-gp130, and monoclonal antiphosphotyrosine antibodies 4G10 were purchased from Upstate Biotechnology Incorporated (Lake Placid, NY, USA). Mouse anti-human IL-6 and IL-6Ra chain Ab were from R&D systems. Ab against human Bax, were from Santa Cruz (Santa Cruz, CA, USA). Anti-Bcl-2 and anti-b-galactosidase Ab were from Boehringer Mannheim (Mannheim, Germany). Rabbit anti-phospho-Elk-1 Ab (Ser383) was from New England Biolabs. Rabbit anti-STAT3 was kindly provided by Dr David Levy, New York University, School of Medicine, New York City, USA.
Plasmids
Wild-type ERK2 and dominant-negative mutant Y185F (Robbins et al., 1993) were kindly provided by Dr Melanie H Cobb, University of Texas, Southwestern Medical Center, Dallas, USA. Wild-type STAT3 and dominant-negative IL-6 prevents apoptosis in human esophageal carcinoma C-M Leu et al mutant STAT3F (Nakajima et al., 1996) were generously provided by Dr Toshio Hirano, Osaka University, Medical School, Osaka, Japan.
Cell culture
A human esophageal carcinoma cell line CE48T/VGH was established in our laboratory (Hu et al., 1984) and routinely cultured in Dulbecco's modified Eagle's medium (DMEM, GIBCO BRL, Grand Island, NY, USA) containing 5% fetal calf serum (FCS). Various numbers of cells were seeded in 24-or 6-well plates overnight and then cultured in SF medium for 24 h. Fresh SF medium containing ST or/and IL-6 was then added to the cells. For the experiments using inhibitors, cells were pretreated with PD98059 for 90 min, wortmannin for 4 h, or Ly294002 for 4 h in SF medium. Fresh SF media containing ST, various concentrations of IL-6 and inhibitors were then added to the cells for appropriate periods as indicated in each experiment.
RT-PCR
Total RNA from CE48T/VGH cells and esophageal carcinoma tissues were purified as described previously (Wong et al., 1994) . cDNA was reversed transcribed (RT) from 1 mg of total RNA using 100 U of SuperScript II reverse transcriptase (GIBCO BRL) and an oligo dT primer (Amersham Pharmacia Biotech, Buckinghamshire, England). Polymerase chain reaction (PCR) was performed in a final volume of 20 ml containing four dNTPs (each at 200 mM), 2.5 U of AmpliTag Gold (PE Biosystems, Foster City, CA, USA), and each primer at 0.4 mM. The samples were 'heat started' at 931C for 10 min, then amplified at 941C for 45 s, 601C for 45 s, and 721C for 1 min for 27 cycles for IL-6 and 20 cycles for human glyceraldehyde 3-phosphate dehydrogenase (G3PDH) gene. The PCR products were separated by electrophoresis on a 2% agarose gel and visualized by ethidium bromide staining. Amplification of G3PDH gene was served as an internal control. Primers used for human IL-6 gene were 5 0 -TCAAT-GAGGAGACTTGCCTG-3 0 and 5 0 -GATGAGTTGT-CATGTCCTGC-3 0 Sequences for G3PDH gene were 5 0 -TGGTAT CGTGGAAGGACTCATGAC-3 0 and 5 0 -ATGC-CAGTGAGCTTCCCGTTCAGC-3 0 (Nobori et al., 1994) .
Immunohistochemical staining
After deparaffinization and dehydration, the sections were microwave-treated in 0.01 M sodium citrate buffer for 5 min and incubated for 30 min at room temperature with 1% hydrogen peroxide (DAKO, USA) for the blocking of the endogenous peroxidase activity. Subsequently, 5 mg/ml of anti-IL-6 mAb (R&D, USA) was added on the sections and incubated overnight at room temperature. Normal mouse IgG was used as a control antibody. The sections were then incubated for 15 min with biotinylated goat anti-mouse Ig. After washing in PBS for 5 min, the sections were incubated with streptavidin conjugated to horseradish peroxidase for 15 min. The sections were then washed and developed with 3,3 0 -diaminobenzidine as the substrate, counterstained with hematoxylin and mounted.
Immunoprecipitation
Cells were washed twice with ice-cold Hank's balanced salt solution (HBSS) and dissolved in NET buffer (50 mM Tris, pH 7.4, 1 mM EDTA, 150 mM NaCl, 0.5% NP-40, 2 mM phenylmethylsulfonyl fluoride (PMSF), 2 mg/ml aprotinin, and 1 mM leupeptin) on ice. For the detection of phosphorylation of proteins, 1 mM sodium vanadate, 80 mM sodium pyrophosphate, and 50 mM sodium fluoride were included in the NET buffer. Protein A-Sepharose beads (20 ml) were washed three times and appropriate amounts of specific Ab were reacted with protein A-Sepharose beads on ice for 30 min. The cell lysates were then mixed with Ab-coated protein A-Sepharose beads on a rotator at 41C for 1 h. The immune complexes were washed three times with NET buffer. A volume of 30 ml of 2 Â sample buffer as added to the beads and incubated at 1001C for 5 min. The soluble portion was subjected to sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Western blot analysis
After SDS-PAGE, separated proteins on acrylamide gel were transferred to nitrocellulose membrane by a semidry blotter (Bio-Rad, Hercules, CA, USA). The membranes were blocked in 5% skim milk in TBS buffer (50 mM Tris, pH 7.4, 150 mM NaCl) at 41C overnight and reacted with specific antibodies. Specific bands were visualized with peroxidase-conjugated secondary antibodies using the enhanced chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech).
Apoptosis assays
Detection of micronucleation by fluorescence microscopy was performed as described previously (Leu et al., 2000) . In brief, 7.5 Â 10 4 cells were seeded into 24-well plates in 5% FCScontaining DMEM. After overnight culture, cells were washed once with HBSS, and then cultured in SF medium for 1 day. Cells were treated with inhibitors or IL-6 for appropriate periods as indicated in each experiment. Both floating and attached cells were collected and fixed in 2% formaldehyde in phosphate-buffered saline (PBS) on slides. Fixed cells were further treated with acetone for 10 min and then stained with 0.5 mg/ml Hoechst 33258 for 10 min. The slides were washed three times with PBS and the morphology of nuclei was observed using fluorescence microscopy. At least 200 cells were counted for each duplicate treatment. The cells containing fragmented nuclei were considered as apoptotic cells (Leu et al., 2000) . For the detection of PARP degradation, both floating and attached cells were collected and dissolved with the sample buffer. The amount of cell lysate equivalent to 2 Â 10 5 cells was applied to each lane and subjected to SDS-PAGE and Western blot analysis. Apoptosis was also measured by the In Situ Cell Detection Kit using terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) (Roche Applied Science, Mannheim, Germany). In brief, both floating and attached cells were collected and fixed with 4% paraformaldehyde for 15 min. Cells were permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 3 min and incubated with TdT and the labeling buffer at 371C for 1 h. Cells were then analysed by flow cytometry.
MAP kinase assay
Cells treated as indicated were washed twice with cold HBSS and lysed with the cell lysis buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EDTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM sodium vanadate, 1 mg/ml leupeptin, and 2 mM PMSF on ice for 5 min. Cell nuclei were removed by centrifugation. Proteins (200 mg) were reacted with 2 mg anti-ERK2 (C-14) Ab at 41C for 3 h. Protein A-Sepharose (30 ml) was mixed with the immune complex for another 1 h. The immunoprecipitates were washed twice with lysis buffer, twice with kinase buffer (25 mM Tris, pH 7.5, 5 mM b-glycerolphos-phate, 2 mM DTT, 0.1 mM sodium vanadate, and 10 mM MgCl 2 ), and suspended in 50 ml of kinase buffer containing 200 mM ATP and 2 mg Elk-1 fusion protein. The kinase reaction was carried out at 301C for 30 min and terminated by the addition of 12.5 ml of 5 Â sample buffer. After boiling, 30 ml of the sample was subjected to SDS-PAGE and immunoblotted with anti-phospho-Elk-1 (Ser383) Ab.
Transient transfection and double staining
For the transfection experiments, 5 mg of pCMV-b (contains bgalactosidase gene driven by CMV) and 15 mg of other DNA were introduced into the cell by electroporation. After washing, 1 Â 10 6 cells were seeded into each well of 24-well plates. After 2 days, cells were washed once, cultured in DMEM containing 0.2% FCS for 24 h, and then treated with 25 or 30 nM ST with or without 100 ng/ml IL-6 in DMEM containing 0.2% FCS. After 2 days, these cells were collected and fixed in 2% formaldehyde and acetone. The transfected cells were identified by the staining of the cells with monoclonal anti-b-galactosidase Ab and Texas-red-conjugated goat anti-mouse antibody. The DNA in the nuclei was stained with 1 mg/ml of Hoechst 33258. The morphology of nuclei (blue fluorescence in the transfected cells and red fluorescence in the cytoplasm) was observed by fluorescence microscopy. The percentages of apoptotic cells with micronucleation were counted.
